Tell the procedure and anaesthetic team about any GLP-1 medicine, including privately prescribed tablets. Do not apply a blanket internet stopping interval: the team needs to balance procedure-specific risks with the consequences of interrupting treatment.
Why the team needs to know
GLP-1 medicines can delay stomach emptying. During general anaesthesia or deep sedation, stomach contents may enter the lungs, a complication called pulmonary aspiration. The MHRA advises clinicians to consider this risk even when usual fasting instructions have been followed. A medicine taken for weight management is therefore relevant to an operation unrelated to weight.
Tell the team at pre-assessment rather than waiting until the day of the procedure. Include dentistry or endoscopy when sedation is planned. A private prescription may not appear on the hospital's medicine list, so do not assume that another service has already passed the information on.
Sources: MHRA: GLP-1 medicines: potential aspiration risk during anaesthesia or deep sedation
Provide the details that shape the plan
Give the brand, generic name, formulation, current strength, dosing frequency and last dose date. Mention recent escalation, missed doses, nausea, vomiting, bloating or difficulty tolerating meals. Explain whether the medicine is also treating diabetes and list other prescriptions, including any separate diabetes medicines.
Ask where this information should be recorded and who will provide the final instructions. If the operation date changes, make sure the medication plan is rechecked. A plan written for a different date or a previous strength may need review rather than being carried forward automatically.
Sources: Centre for Perioperative Care / UK multidisciplinary consensus group: Patient information: GLP-1 medicines and preparing for surgery; MHRA: GLP-1 medicines: potential aspiration risk during anaesthesia or deep sedation
Do not choose a stopping interval yourself
UK multidisciplinary guidance emphasises an individual plan and consideration of the potential harms of both continuing and stopping. The MHRA notes that UK product information does not provide a universal withholding schedule before anaesthesia or deep sedation. Advice from another country, an older article or a different procedure may not match your circumstances.
Ask directly what to do with the next dose and which team should resolve any conflicting instructions. Do not independently lengthen fasting, stop essential diabetes treatment or assume that missing one dose removes every risk. The anaesthetic team may manage risk through measures other than stopping the medicine.
Sources: MHRA: GLP-1 medicines: potential aspiration risk during anaesthesia or deep sedation; Centre for Perioperative Care / UK multidisciplinary consensus group: Patient information: GLP-1 medicines and preparing for surgery
Follow the procedure team's fasting instructions
The fasting plan for a procedure is different from oral semaglutide's ordinary administration routine. Obtain instructions that cover food, drink and all morning medicines. If anything is unclear, contact the procedure team before the appointment rather than trying to combine several leaflets into your own plan.
On the day, disclose any dose taken differently from the agreed plan, any food or drink outside the instructions and any new digestive symptoms. Accurate information helps the team decide how to proceed. Do not hide a deviation out of concern that the procedure might be delayed.
Sources: Centre for Perioperative Care / UK multidisciplinary consensus group: Patient information: GLP-1 medicines and preparing for surgery; Novo Nordisk / electronic medicines compendium: Wegovy tablets: UK Summary of Product Characteristics
Include the period after the procedure
Before discharge, ask when the medicine should be resumed, whether the previous dose remains appropriate after a gap and who will handle ongoing prescriptions. Explain if eating or drinking is still difficult. If diabetes is involved, obtain the monitoring and other-medicine instructions as part of the same discharge plan.
Share the outcome with the weight-management prescriber if it is a separate service. Do not restart automatically from an old high-strength supply after a prolonged interruption. For urgent surgery, tell the treating team the medicine and last dose as soon as possible; arranging a medication plan must not delay emergency care.
Sources: Centre for Perioperative Care / UK multidisciplinary consensus group: Patient information: GLP-1 medicines and preparing for surgery; Novo Nordisk / electronic medicines compendium: Wegovy FlexTouch: UK Summary of Product Characteristics; General Pharmaceutical Council and UK health organisations: How to keep safe when getting medicines or treatment online
Questions, answered.
Should everyone stop a weekly injection seven days before surgery?
Do not apply a universal rule. The procedure and anaesthetic team should provide instructions for your medicine, indication and circumstances.
Sources: MHRA: GLP-1 medicines: potential aspiration risk during anaesthesia or deep sedation; Centre for Perioperative Care / UK multidisciplinary consensus group: Patient information: GLP-1 medicines and preparing for surgery
Do I need to mention a daily tablet as well as an injection?
Yes. Tell the team about all GLP-1 treatment and the exact formulation; oral treatment is still relevant to the assessment.
Sources: Novo Nordisk / electronic medicines compendium: Wegovy tablets: UK Summary of Product Characteristics; Eli Lilly / electronic medicines compendium: Foundayo: UK Summary of Product Characteristics, revised 3 November 2026
Sources & further reading
Original sources for this guide. Source checks are not independent clinical review.
- GLP-1 medicines: potential aspiration risk during anaesthesia or deep sedationMHRA · Accessed 19 November 2026
- Patient information: GLP-1 medicines and preparing for surgeryCentre for Perioperative Care / UK multidisciplinary consensus group · Accessed 19 November 2026
- Wegovy tablets: UK Summary of Product CharacteristicsNovo Nordisk / electronic medicines compendium · Accessed 19 November 2026
- Wegovy FlexTouch: UK Summary of Product CharacteristicsNovo Nordisk / electronic medicines compendium · Accessed 19 November 2026
- How to keep safe when getting medicines or treatment onlineGeneral Pharmaceutical Council and UK health organisations · Accessed 19 November 2026
- Foundayo: UK Summary of Product Characteristics, revised 3 November 2026Eli Lilly / electronic medicines compendium · Accessed 19 November 2026
